Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Gamma-aminobutyric acid type A (GABA-A) receptor is a pentameric, ligand-gated ion channel that serves as the primary mediator of rapid inhibitory neurotransmission in the mammalian central nervous system (PubChem). It typically consists of a combination of subunits (most commonly two alpha, two beta, and one gamma), which form a central pore permeable to chloride ions; binding of the neurotransmitter GABA triggers channel opening, leading to neuronal hyperpolarization and reduced excitability (Wikipedia, Hammer et al. 2015). This receptor is the primary therapeutic target for the drug Methaqualone (commonly known as Quaalude), which was historically used as a potent sedative-hypnotic for treating insomnia and anxiety before being largely withdrawn due to its high abuse potential (Britannica, PBS News). Methaqualone acts as a selective positive allosteric modulator of the GABA-A receptor, binding to a specific transmembrane site at the beta(+)/alpha(-) subunit interface that is distinct from the binding sites for benzodiazepines and barbiturates (Hammer et al. 2015, Nature Communications). By enhancing the inhibitory effects of GABA, methaqualone induces significant sedation, muscle relaxation, and anticonvulsant activity (ResearchGate). Dysregulation of GABA-A receptor signaling is fundamentally linked to neurological and psychiatric disorders such as epilepsy, anxiety, and insomnia. Despite its efficacy, targeting this receptor with potent agents like methaqualone carries severe risks, including life-threatening respiratory depression, rapid development of tolerance, and a dangerous withdrawal syndrome (StatPearls, Britannica).
Positive allosteric modulation of the GABA-A receptor, primarily through binding to the transmembrane beta(+)/alpha(-) subunit interface to enhance the receptor's affinity for GABA and increase chloride ion conductance.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gamma-aminobutyric acid type A receptor (GABA-A receptor) (GABA-A receptor).